Literature DB >> 4570454

The coronary drug project. Design, methods, and baseline results.

.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4570454     DOI： 10.1161/01.cir.47.3s1.i-1

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

1.  Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.

Authors:  Jun Qin; Ashwin Rao; Xiao Chen; Xiaohong Zhu; Zhidan Liu; Xianhai Huang; Sylvia Degrado; Ying Huang; Dong Xiao; Robert Aslanian; Boonlert Cheewatrakoolpong; Hongtao Zhang; Scott Greenfeder; Constance Farley; John Cook; Stan Kurowski; Qiu Li; Margaret van Heek; Madhu Chintala; Ganfeng Wang; Yunsheng Hsieh; Fangbiao Li; Anandan Palani
Journal:  ACS Med Chem Lett       Date:  2010-12-08       Impact factor: 4.345

Review 2.  Regulation of NAD+ metabolism in aging and disease.

Authors:  Xiaogang Chu; Raghavan Pillai Raju
Journal:  Metabolism       Date:  2021-10-28       Impact factor: 8.694

3.  Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials.

Authors:  Eleanor J Murray; Miguel A Hernán
Journal:  Clin Trials       Date:  2016-03-07       Impact factor: 2.486

4.  Long-term physiological T3 supplementation in hypertensive heart disease in rats.

Authors:  Nathan Y Weltman; Christine J Pol; Youhua Zhang; Yibo Wang; Adrienne Koder; Sarah Raza; Riccardo Zucchi; Alessandro Saba; Daria Colligiani; A Martin Gerdes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

5.  Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.

Authors:  William Insull; Peter P Toth; H Robert Superko; Roopal B Thakkar; Scott Krause; Ping Jiang; Rhea A Parreno; Robert J Padley
Journal:  Vasc Health Risk Manag       Date:  2010-11-24

6.  Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.

Authors:  Helen Vosper
Journal:  Clin Med Insights Cardiol       Date:  2011-09-19

Review 7.  Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

Authors:  Alexander Tenenbaum; Enrique Z Fisman; Michael Motro; Yehuda Adler
Journal:  Cardiovasc Diabetol       Date:  2006-09-26       Impact factor: 9.951

Review 8.  Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.

Authors:  Richard L Dunbar; Harsh Goel
Journal:  Curr Atheroscler Rep       Date:  2016-02       Impact factor: 5.113

9.  Improved adherence adjustment in the Coronary Drug Project.

Authors:  Eleanor J Murray; Miguel A Hernán
Journal:  Trials       Date:  2018-03-05       Impact factor: 2.279

10.  Recruitment to randomised studies.

Authors:  Wendy E Hague; Val J Gebski; Anthony C Keech
Journal:  Med J Aust       Date:  2003-06-02       Impact factor: 7.738
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.